2024-10-10T17:24:40+08:002024-07-10|
Contact Information
Research Team
Name Position Office Phone Email
Xiaolei LINResearch Assistant (Lab Representative)xiaoleilin@um.edu.mo
Education
PhD University of Macau, China (2017)
MMed Beijing University of Chinese Medicine, China (2013)
BEng Beijing University of Chinese Medicine , China (2011)
Positions
2024 – Present Assistant Professor, Faculty of Health Sciences, University of Macau
2023 – 2024 Research Associate, Montreal Clinical Research Institute, Montreal, Quebec, Canada
2017 – 2023 Postdoctoral Fellow, Montreal Clinical Research Institute, Montreal, Quebec, Canada
Research Interests
  1. Providing an in-depth mechanistic understanding of immune checkpoints for rational development of first-in-class monoclonal antibodies, bispecific antibodies and antibody-drug conjugates.
  2. Screening novel immune checkpoints by CRISPR with specific sgRNA library for cancer therapy.
  3. Developing CAR macrophages against cancer.
Representative Publications
First and co-first# author articles :

  1. Tang Z, Zhong MC, Qian J, Galindo CC, Davidson D, Li J, Zhao Y, Hui E, Veillette A: CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress anti-tumor immunity. Nature Immunology 2023, 24: 2032–2041.
  2. Tang Z, Veillette A: Combining a first-in-class SLAMF7 antibody with SIRPα blockade for anti-tumor immunity. Nature Immunology 2023, 24: 1978–1979.
  3. Tang Z, Veillette A: Improving treatment of solid cancers by nanoconjugate-mediated immune conversion of tumour cells. Nature Nanotechnology 2022, 17:1243-4.
  4. Tang Z#, Davidson D#, Li R, Zhong MC, Qian J, Chen J, Veillette A: Inflammatory macrophages exploit unconventional pro-phagocytic integrins for phagocytosis and anti-tumor immunity. Cell Reports 2021, 37:110111.
  5. Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, Lu JJ: Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. Cancer Letters 2018, 412:1-9.
  6. Tang ZH, Lu JJ: Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Letters 2018, 420:242-6.
  7. Tang ZH#, Su MX#, Guo X, Jiang XM, Jia L, Chen X, Lu JJ: Increased Expression of IRE1alpha Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant non-small Cell Lung Cancer HCC827/OSIR Cells. Anti-Cancer Agents in Medicinal Chemistry 2018, 18:550-5.
  8. Tang ZH#, Cao WX#, Wang ZY, Lu JH, Liu B, Chen X, Lu JJ: Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells. Redox Biology 2017, 12:367-76.
  9. Tang ZH, Cao WX, Su MX, Chen X, Lu JJ: Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicology and Applied Pharmacology 2017, 321:18-26.
  10. Tang ZH#, Guo X#, Cao WX, Chen X, Lu JJ: Fangchinoline accumulates autophagosomes by inhibiting autophagic degradation and promoting TFEB nuclear translocation. RSC Advances 2017, 7:42597-605.
  11. Tang ZH, Chen X, Wang ZY, Chai K, Wang YF, Xu XH, Wang XW, Lu JH, Wang YT, Chen XP, Lu JJ: Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. Scientific Reports 2016, 6:1-10.
  12. Tang ZH#, Jiang XM#, Guo X, Fong CMV, Chen X, Lu JJ: Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. Oncotarget 2016, 7:81598.
  13. Tang ZH, Li T, Tong YG, Chen XJ, Chen XP, Wang YT, Lu JJ: A systematic review of the anticancer properties of compounds isolated from Licorice (Gancao). Planta Medica 2015, 81:1670-87.
  14. Tang ZH, Zhang LL, Li T, Lu JH, Ma DL, Leung CH, Chen XP, Jiang HL, Wang YT, Lu JJ: Glycyrrhetinic acid induces cytoprotective autophagy via the inositol-requiring enzyme 1α-c-Jun N-terminal kinase cascade in non-small cell lung cancer cells. Oncotarget 2015, 6:43911.
  15. Chen XJ#, Tang ZH#, Li XW, Xie CX, Lu JJ, Wang YT: Chemical constituents, quality control, and bioactivity of Epimedii Folium (Yinyanghuo). American Journal of Chinese Medicine 2015, 43:783-834.
  16. Tang ZH, Li T, Chang LL, Zhu H, Tong YG, Chen XP, Wang YT, Lu JJ: Glycyrrhetinic Acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. Journal of Agricultural and Food Chemistry 2014, 62:11910-6.

Other articles :

  1. Li B, Lu Y, Zhong MC, Qian J, Li R, Davidson D, Tang Z, Zhu K, Argenty J, de Peredo AG, Malissen B, Roncagalli R, Veillette A: Cis interactions between CD2 and its ligands on T cells are required for T cell activation. Science Immunology 2022, 7:eabn6373.
  2. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ: Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology 2020, 175:113921.
  3. Veillette A, Tang Z: Signaling Regulatory Protein (SIRP)alpha-CD47 Blockade Joins the Ranks of Immune Checkpoint Inhibition. Journal of Clinical Oncology 2019, 37:1012-4.
  4. Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, Lu JJ: MLKL mediates apoptosis via a mutual regulation with PERK/eIF2alpha pathway in response to reactive oxygen species generation. Apoptosis 2018, 23:521-31.
  5. Wang YF, Tang ZH, Li T, Xu XH, Chen X, Wang Y, Wang YT, Lu JJ: Baicalein protects tert‑butyl hydroperoxide‑induced hepatotoxicity dependent of reactive oxygen species removal. Molecular Medicine Reports 2017, 16:8392-8.
  6. Wang YF, Xu YL, Tang ZH, Li T, Zhang LL, Chen X, Lu JH, Leung CH, Ma DL, Qiang WA, Wang YT, Lu JJ: Baicalein Induces Beclin 1- and Extracellular Signal-Regulated Kinase-Dependent Autophagy in Ovarian Cancer Cells. American Journal of Chinese Medicine 2017, 45:123-36.
  7. Wang FZ, Xing L, Tang ZH, Lu JJ, Cui PF, Qiao JB, Jiang L, Jiang HL, Zong L: Codelivery of doxorubicin and shAkt1 by poly (ethylenimine)–glycyrrhetinic acid nanoparticles to induce autophagy-mediated liver cancer combination therapy. Molecular Pharmaceutics 2016, 13:1298-307.
  8. Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X, Li T, Ding CY, Huang MQ, Chen XP, Wang YT, Yuan XF, Lu JJ: Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. Phytomedicine 2016, 23:800-9.
  9. Wang X, Zhou J, Chen B, Tang Z, Zhang J, Li L, Tang J: Enhanced intracellular hyperthermia efficiency by magnetic nanoparticles modified with nucleus and mitochondria targeting peptides. Journal of Nanoscience and Nanotechnology 2016, 16:6560-6.
  10. Chen X, Wu QS, Meng FC, Tang ZH, Chen X, Lin LG, Chen P, Qiang WA, Wang YT, Zhang QW, Lu JJ: Chikusetsusaponin IVa methyl ester induces G1 cell cycle arrest, triggers apoptosis and inhibits migration and invasion in ovarian cancer cells. Phytomedicine 2016, 23:1555-65.
  11. Zhang LL, Tian K, Tang ZH, Chen XJ, Bian ZX, Wang YT, Lu JJ: Phytochemistry and Pharmacology of Carthamus tinctorius L. American journal of Chinese medicine 2016, 44:197-226.
  12. Li T, Tang ZH, Xu WS, Wu GS, Wang YF, Chang LL, Zhu H, Chen XP, Wang YT, Chen Y, Lu JJ: Platycodin D triggers autophagy through activation of extracellular signal-regulated kinase in hepatocellular carcinoma HepG2 cells. European Journal of Pharmacology 2015, 749:81-8.
  13. Li T, Xu XH, Tang ZH, Wang YF, Leung CH, Ma DI, Chen XP, Wang YT, Chen Y, Lu JJ: Platycodin D induces apoptosis and triggers ERK-and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Acta Pharmacologica Sinica 2015, 36:1503-13.
  14. Wang YF, Li T, Tang ZH, Chang LL, Zhu H, Chen XP, Wang YT, Lu JJ: Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells. Phytotherapy Research 2015, 29:674-9.
Research Grants
2019 Cole Foundation: Targeting the SIRP α-CD47 Immune Checkpoint Against non Hodgkin’s Lymphoma (Role: Principal Investigator 84000 CAD)
Awards
2018 Angelo Pizzagalli Scholarship, Montreal Clinical Re search Institute, Montreal, Quebec, Canada
2013 – 2016 University of Macau PhD Scholarship, University of Macau, Macau , China
Professional Activities
Youth Editorial Board Member
2022 – Present Chinese Medicine (IF=4.9)
Journal Paper Reviewer
  • Acta Pharmaceutica Sinica B
  • Biomedicine & Pharmacotherapy
  • Biomedical and Environmental Sciences
  • Cancer Letters
  • Cell Communication and Signaling
  • Cell Reports
  • Chinese Journal of Natural Medicines
  • Frontiers in Immunology
  • Heliyon
  • Journal of Experimental & Clinical Cancer Research
  • Molecular and Cellular Biology
  • Phytomedicine
  • Phytotherapy Research